The Experts below are selected from a list of 8361 Experts worldwide ranked by ideXlab platform
Karl Rickels - One of the best experts on this subject based on the ideXlab platform.
-
interaction between polymorphisms in serotonin transporter slc6a4 and serotonin receptor 2a htr2a genes predict treatment response to venlafaxine xr in generalized Anxiety disorder
Pharmacogenomics Journal, 2013Co-Authors: Falk W Lohoff, Sneha Narasimhan, Karl RickelsAbstract:Variation in genes involved in serotonergic signaling is thought to be associated with antidepressant treatment response in generalized Anxiety disorder (GAD). We examined a possible interaction between the serotonin transporter gene (SLC6A4) 5-HTTLPR/rs25531 haplotype and the serotonin 2A receptor gene (HTR2A) single-nucleotide polymorphism (SNP) rs7997012 in antidepressant treatment outcome in GAD. Patients diagnosed with GAD received venlafaxine XR treatment as part of an 18-month relapse prevention study. Genotypes obtained for the 5-HTTLPR/rs25531 (La/La, La/S or S/S) haplotype and rs7997012 SNP (G or A) in the European American population (n=112) were used for pharmacogenetic analysis. Our data show that subjects with genotypes La/La+G/G or La/La+G/A (n=28) had significantly lower Hamilton Anxiety Scale (HAM-A) scores than those with genotypes La/S+A/A or S/S+A/A (n=12) at 6 months (HAM-A difference=10.7; P<0.0001). Single-marker analysis only showed HAM-A differences of 4.3 (5-HTTLPR/rs25531: La/La versus La/S+S/S) and 4.8 (rs7997012: G/G+G/A versus A/A), showing for the first time a significant gene–gene interaction between these markers.
-
paroxetine treatment of generalized Anxiety disorder a double blind placebo controlled study
American Journal of Psychiatry, 2003Co-Authors: Karl Rickels, Rocco Zaninelli, James P Mccafferty, Kevin M Bellew, Malini K Iyengar, David V SheehanAbstract:Objective: This study assessed the efficacy of two fixed doses of paroxetine in the treatment of generalized Anxiety disorder. Method: Outpatients (N=566) with generalized Anxiety disorder and no other axis I disorder were eligible if they scored ≥20 on the Hamilton Rating Scale for Anxiety (with a score of 2 or higher on the anxious mood and tension items). Following a 1-week placebo run-in phase, patients were randomly assigned to 8 weeks of treatment with paroxetine, 20 or 40 mg/day, or placebo. The primary outcome measure was the change from baseline in total score on the Hamilton Anxiety Scale. Response was defined as a rating of “very much improved” or “much improved” on the Clinical Global Impression global improvement measure; remission was defined as a Hamilton Anxiety Scale score ≤7. Change in functional impairment was measured with the Sheehan Disability
-
Placebo-Controlled Trial of Sertraline in the Treatment of Children With Generalized Anxiety Disorder
The American journal of psychiatry, 2001Co-Authors: Moira A. Rynn, Lynne Siqueland, Karl RickelsAbstract:OBJECTIVE: The study compared the safety and efficacy of sertraline, a selective serotonin reuptake inhibitor, and placebo in the treatment of generalized Anxiety disorder in children and adolescents. METHOD: The study subjects were 22 children and adolescents age 5–17 years who met the DSM-IV criteria for generalized Anxiety disorder according to the Anxiety Disorders Interview Schedule for Children—Revised and who had a Hamilton Anxiety Rating Scale score ≥16. The patients underwent a 2–3-week prestudy evaluation period, followed by a 9-week double-blind treatment phase in which they were randomly assigned in blocks of four to receive either sertraline or pill placebo. The maximum dose of sertraline was 50 mg/day. Primary outcome measures were the Hamilton Anxiety Scale and the Clinical Global Impression Scale. RESULTS: The Hamilton Anxiety Scale total score, psychic factor, and somatic factor and the Clinical Global Impression severity and improvement Scales showed significant differences with treatmen...
-
efficacy of extended release venlafaxine in nondepressed outpatients with generalized Anxiety disorder
American Journal of Psychiatry, 2000Co-Authors: Karl Rickels, Mark H Pollack, David V Sheehan, J T HaskinsAbstract:OBJECTIVE: This study evaluated the efficacy and safety of fixed doses of once-daily extended-release (XR) venlafaxine in outpatients with generalized Anxiety disorder without concomitant major depressive disorder. METHOD: Adult outpatients with generalized Anxiety disorder but not major depressive disorder with total scores of 18 or higher on the Hamilton Rating Scale for Anxiety and scores of 2 or higher on its anxious mood and tension factors were eligible. Patients were randomly assigned to receive placebo or venlafaxine XR (75, 150, or 225 mg/day) for 8 weeks. Primary efficacy variables were final total and psychic Anxiety factor scores on the Hamilton Anxiety Scale and final severity and global improvement item scores on the Clinical Global Impression (CGI) Scale. RESULTS: Of the 377 patients entering the study, 370 were included in a safety analysis and 349 in an efficacy analysis. Adjusted mean scores at 8 weeks (last-observation-carried-forward analysis) were significantly lower for one or more of the venlafaxine XR groups in four of four primary and three of four secondary outcome measures than for the placebo group. These included a change of 1.7 (versus 1.3) from baseline on CGI severity item scores and a final score of 2.2 (versus 2.6) on the CGI global improvement item. All doses of venlafaxine XR were well tolerated. CONCLUSIONS: Venlafaxine XR is an effective and well-tolerated option for the short-term treatment of generalized Anxiety disorder in outpatients without major depressive disorder.
Jaime Tortoriello - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and tolerability of a standardized herbal product from galphimia glauca on generalized Anxiety disorder a randomized double blind clinical trial controlled with lorazepam
Planta Medica, 2007Co-Authors: Armando Herreraarellano, Enrique Jimenezferrer, Alejandro Zamilpa, Marisol Moralesvaldez, Claudia E Garciavalencia, Jaime TortorielloAbstract:GALPHIMIA GLAUCA Cav. is a plant used in Mexican traditional medicine as a ”nerve tranquilizer”. Previous studies have demonstrated that the methanolic extract from this plant species possess an anxiolytic effect. Galphimine B (GB, a nor-seco-triterpene), is the active principle, with an innovative action mechanism. Against this background, a standardized herbal medicinal product was developed from the aqueous extract of G. GLAUCA (GgHP). The present work compared the therapeutic effectiveness, safety, and tolerability of the new GgHP with lorazepam on patients with generalized Anxiety disorder (GAD). By means of a controlled, randomized, double-blind clinical trial, outpatients of either sex who matched the DSM-IV diagnostic criteria with a score of ≥ 19 points on the Hamilton Anxiety Scale (HAM-A) were included. The experimental group was treated orally with GgHP in capsules twice a day for 4 weeks. The control group received lorazepam (1 mg) under the same conditions and presentation. A total of 152 patients were included in the trial (72 in the experimental group). From the first week of treatment, GgHP showed important anxiolytic effectiveness, very similar to that produced with lorazepam. Both treatments showed therapeutic safety (no alterations on biochemical analysis of hepatic and renal function). Nevertheless, concerning side effects, GgHP evidenced a considerably higher tolerability than lorazepam. ALP: alkaline phosphatase ALT: alanine aminotransferase AST: aspartate aminotransferase GAD: generalized Anxiety disorder GB: galphimine B GgHP: standardized herbal medicinal product from the aqueous extract of GALPHIMIA GLAUCAHAM-A: Hamilton Anxiety Scale SSRI: selective serotonin reuptake inhibitors
-
efficacy and tolerability of a standardized herbal product from galphimia glauca on generalized Anxiety disorder a randomized double blind clinical trial controlled with lorazepam
Planta Medica, 2007Co-Authors: Armando Herreraarellano, Enrique Jimenezferrer, Alejandro Zamilpa, Marisol Moralesvaldez, Claudia E Garciavalencia, Jaime TortorielloAbstract:Galphimia glauca Cav. is a plant used in Mexican traditional medicine as a "nerve tranquilizer". Previous studies have demonstrated that the methanolic extract from this plant species possess an anxiolytic effect. Galphimine B (GB, a nor-seco-triterpene), is the active principle, with an innovative action mechanism. Against this background, a standardized herbal medicinal product was developed from the aqueous extract of G. glauca (GgHP). The present work compared the therapeutic effectiveness, safety, and tolerability of the new GgHP with lorazepam on patients with generalized Anxiety disorder (GAD). By means of a controlled, randomized, double-blind clinical trial, outpatients of either sex who matched the DSM-IV diagnostic criteria with a score of > or = 19 points on the Hamilton Anxiety Scale (HAM-A) were included. The experimental group was treated orally with GgHP in capsules twice a day for 4 weeks. The control group received lorazepam (1 mg) under the same conditions and presentation. A total of 152 patients were included in the trial (72 in the experimental group). From the first week of treatment, GgHP showed important anxiolytic effectiveness, very similar to that produced with lorazepam. Both treatments showed therapeutic safety (no alterations on biochemical analysis of hepatic and renal function). Nevertheless, concerning side effects, GgHP evidenced a considerably higher tolerability than lorazepam.
Xiang Yang Zhang - One of the best experts on this subject based on the ideXlab platform.
-
the relationship between overweight and thyroid function in first episode untreated chinese patients with major depressive disorder with different ages of onset
Journal of Affective Disorders, 2021Co-Authors: Yuanyuan Huang, Xiaoe Lang, Xiang Yang Zhang, Xiaocui Zang, Zhimin Zhu, Mingzhe YangAbstract:Abstract Background Major depressive disorder (MDD) and obesity are common. There are many differences in many aspects of MDD patients at different ages of onset (AOO); however, there are currently no studies on differences in obesity or overweight. This study aims to evaluate whether thyroid function changes with body weight, and to explore the related factors of overweight in MDD patients with different AOOs. Methods A total of 1716 first-episode, untreated Chinese Han outpatients with MDD were recruited from a general hospital. Hamilton Anxiety Scale (HAMA), Hamilton Depression Scale (HAMD) and Positive Symptom subScale of the Positive and Negative Syndrome Scale (PANSS) were used to evaluate Anxiety, depression and psychotic symptoms, respectively. The participants were divided into two groups: early adulthood onset (EAO, =45 years old). Results Compared with EAO patients, MAO patients scored higher on the HAMD, HAMA, CGI-S and PANSS positive symptoms subScale, and they also had higher systolic and diastolic blood pressure (BP), higher serum levels of thyroid stimulating hormone (TSH), FBG, cholesterol (TC) and low-density lipoprotein, but they had lower serum levels of free triiodothyronine 3 and high-density lipoprotein. TSH, anti-thyroglobulin (TgAb), TC and systolic BP were correlated with overweight in MAO patients, while TSH and FBG were correlated with overweight of EAO patients. Conclusions The results indicate that TSH is related to overweight in both AOO subgroups, and the influencing factors of overweight related to thyroid function may be different in different AOOs.
-
identifying clinical risk factors correlate with suicide attempts in patients with first episode major depressive disorder
Journal of Affective Disorders, 2021Co-Authors: Serik Tabarak, Zengchang Qin, Yuan Chai, Shunyu Zhang, Keqiang Wang, Hengyong Guan, Yingnan Chen, Hongmei Chen, Long Zhao, Xiang Yang ZhangAbstract:Abstract Background Major depressive disorder (MDD) is the most common mental disorder associated with suicide attempts. When a patient first visits the clinic, clinicians are often expected to make concrete diagnose about acute suicidal risk. However, the timeliness of suicide attempts correlates with patients with MDD has not been tested. Methods We divided 1718 first-episode and untreated MDD outpatients into those who did not have suicide attempts (non-attempts), recent suicide attempters (≤14 days before assessment) and long - dated suicide attempters (> 30 days before assessment). Positive Symptom Scale of Positive and Negative Syndrome Scale (PANSS), the 17-item Hamilton Depression Scale, 14 - item Hamilton Anxiety Scale, and clinical global impression of severity Scale (CGI-S) was assessed. Body mass index, some glycolipid metabolism and thyroid hormone parameters were measured. A gradient-boosted decision trees statistical model was used to generate equally weighted classification for distinguishing recent and long - dated suicide attempters from non-attempts. Results The classifier identified higher excitement, hostility, Anxiety, depression symptoms and higher free thyroxine (FT4) as risk factors for recent suicide attempters with an estimated accuracy of 87% (sensitivity, 59.1%; specificity, 61.2 %). For long - dated suicide attempters’ risk factors, single status, higher Anxiety and hostility symptoms, higher LDLC and lower BMI, the estimated accuracy was 88% (sensitivity, 52.8%; specificity, 49.6%). Conclusions Risk factors for suicide attempt among patients with MDD can be identified by integrating demographic, clinical, and biological variables as early as possible during the first time see a doctor.
-
prevalence and clinical profiles of comorbid Anxiety in first episode and drug naive patients with major depressive disorder
Journal of Affective Disorders, 2019Co-Authors: Wanqiu Yang, Guangya Zhang, Qiufang Jia, Zhengkang Qian, Guangzhong Yin, Xiaomin Zhu, Omar I Alnatour, Tammy H Trinh, Xiaoe Lang, Xiang Yang ZhangAbstract:Abstract Background Anxiety is a common comorbidity in major depressive disorder (MDD) that has been studied extensively in the past. However, few studies have explored Anxiety in drug naive (FEDN) patients with MDD and those presenting with a first episode. The objective of this current study was to examine the prevalence and risk factors of Anxiety in FEDN patients with MDD in order to understand the relationship between MDD and Anxiety in the acute early phase and provide important implications for therapeutic interventions. Methods A total of 1718 FEDN patients with MDD were recruited in this cross-sectional study. Their anthropometric and clinical data, including suicide attempt and psychotic symptom, were collected. The Hamilton depression Scale (HAMD) and Hamilton Anxiety Scale (HAMA) were used to evaluate depression and Anxiety for all the patients in this study. Results Overall, we found that the prevalence of Anxiety in FEDN MDD patients was 80.3%. Correlation analysis showed that Anxiety was associated with suicide attempt and psychotic symptom in FEDN patients with MDD. The rate of suicide attempt and psychosis in above patients with Anxiety was 24.3% and 12.3%, respectively. Furthermore, stepwise regression analysis showed that suicide attempt and psychotic symptom were significant predictors for Anxiety in FEDN patients with MDD. Conclusions Our study showed that the prevalence of comorbid Anxiety in FEDN patients with MDD is very high. We also found that two clinical variables, suicide attempt and psychosis, are risk factors for comorbid Anxiety in FEDN patients with MDD.
Armando Herreraarellano - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and tolerability of a standardized herbal product from galphimia glauca on generalized Anxiety disorder a randomized double blind clinical trial controlled with lorazepam
Planta Medica, 2007Co-Authors: Armando Herreraarellano, Enrique Jimenezferrer, Alejandro Zamilpa, Marisol Moralesvaldez, Claudia E Garciavalencia, Jaime TortorielloAbstract:GALPHIMIA GLAUCA Cav. is a plant used in Mexican traditional medicine as a ”nerve tranquilizer”. Previous studies have demonstrated that the methanolic extract from this plant species possess an anxiolytic effect. Galphimine B (GB, a nor-seco-triterpene), is the active principle, with an innovative action mechanism. Against this background, a standardized herbal medicinal product was developed from the aqueous extract of G. GLAUCA (GgHP). The present work compared the therapeutic effectiveness, safety, and tolerability of the new GgHP with lorazepam on patients with generalized Anxiety disorder (GAD). By means of a controlled, randomized, double-blind clinical trial, outpatients of either sex who matched the DSM-IV diagnostic criteria with a score of ≥ 19 points on the Hamilton Anxiety Scale (HAM-A) were included. The experimental group was treated orally with GgHP in capsules twice a day for 4 weeks. The control group received lorazepam (1 mg) under the same conditions and presentation. A total of 152 patients were included in the trial (72 in the experimental group). From the first week of treatment, GgHP showed important anxiolytic effectiveness, very similar to that produced with lorazepam. Both treatments showed therapeutic safety (no alterations on biochemical analysis of hepatic and renal function). Nevertheless, concerning side effects, GgHP evidenced a considerably higher tolerability than lorazepam. ALP: alkaline phosphatase ALT: alanine aminotransferase AST: aspartate aminotransferase GAD: generalized Anxiety disorder GB: galphimine B GgHP: standardized herbal medicinal product from the aqueous extract of GALPHIMIA GLAUCAHAM-A: Hamilton Anxiety Scale SSRI: selective serotonin reuptake inhibitors
-
efficacy and tolerability of a standardized herbal product from galphimia glauca on generalized Anxiety disorder a randomized double blind clinical trial controlled with lorazepam
Planta Medica, 2007Co-Authors: Armando Herreraarellano, Enrique Jimenezferrer, Alejandro Zamilpa, Marisol Moralesvaldez, Claudia E Garciavalencia, Jaime TortorielloAbstract:Galphimia glauca Cav. is a plant used in Mexican traditional medicine as a "nerve tranquilizer". Previous studies have demonstrated that the methanolic extract from this plant species possess an anxiolytic effect. Galphimine B (GB, a nor-seco-triterpene), is the active principle, with an innovative action mechanism. Against this background, a standardized herbal medicinal product was developed from the aqueous extract of G. glauca (GgHP). The present work compared the therapeutic effectiveness, safety, and tolerability of the new GgHP with lorazepam on patients with generalized Anxiety disorder (GAD). By means of a controlled, randomized, double-blind clinical trial, outpatients of either sex who matched the DSM-IV diagnostic criteria with a score of > or = 19 points on the Hamilton Anxiety Scale (HAM-A) were included. The experimental group was treated orally with GgHP in capsules twice a day for 4 weeks. The control group received lorazepam (1 mg) under the same conditions and presentation. A total of 152 patients were included in the trial (72 in the experimental group). From the first week of treatment, GgHP showed important anxiolytic effectiveness, very similar to that produced with lorazepam. Both treatments showed therapeutic safety (no alterations on biochemical analysis of hepatic and renal function). Nevertheless, concerning side effects, GgHP evidenced a considerably higher tolerability than lorazepam.
David V Sheehan - One of the best experts on this subject based on the ideXlab platform.
-
paroxetine treatment of generalized Anxiety disorder a double blind placebo controlled study
American Journal of Psychiatry, 2003Co-Authors: Karl Rickels, Rocco Zaninelli, James P Mccafferty, Kevin M Bellew, Malini K Iyengar, David V SheehanAbstract:Objective: This study assessed the efficacy of two fixed doses of paroxetine in the treatment of generalized Anxiety disorder. Method: Outpatients (N=566) with generalized Anxiety disorder and no other axis I disorder were eligible if they scored ≥20 on the Hamilton Rating Scale for Anxiety (with a score of 2 or higher on the anxious mood and tension items). Following a 1-week placebo run-in phase, patients were randomly assigned to 8 weeks of treatment with paroxetine, 20 or 40 mg/day, or placebo. The primary outcome measure was the change from baseline in total score on the Hamilton Anxiety Scale. Response was defined as a rating of “very much improved” or “much improved” on the Clinical Global Impression global improvement measure; remission was defined as a Hamilton Anxiety Scale score ≤7. Change in functional impairment was measured with the Sheehan Disability
-
efficacy of extended release venlafaxine in nondepressed outpatients with generalized Anxiety disorder
American Journal of Psychiatry, 2000Co-Authors: Karl Rickels, Mark H Pollack, David V Sheehan, J T HaskinsAbstract:OBJECTIVE: This study evaluated the efficacy and safety of fixed doses of once-daily extended-release (XR) venlafaxine in outpatients with generalized Anxiety disorder without concomitant major depressive disorder. METHOD: Adult outpatients with generalized Anxiety disorder but not major depressive disorder with total scores of 18 or higher on the Hamilton Rating Scale for Anxiety and scores of 2 or higher on its anxious mood and tension factors were eligible. Patients were randomly assigned to receive placebo or venlafaxine XR (75, 150, or 225 mg/day) for 8 weeks. Primary efficacy variables were final total and psychic Anxiety factor scores on the Hamilton Anxiety Scale and final severity and global improvement item scores on the Clinical Global Impression (CGI) Scale. RESULTS: Of the 377 patients entering the study, 370 were included in a safety analysis and 349 in an efficacy analysis. Adjusted mean scores at 8 weeks (last-observation-carried-forward analysis) were significantly lower for one or more of the venlafaxine XR groups in four of four primary and three of four secondary outcome measures than for the placebo group. These included a change of 1.7 (versus 1.3) from baseline on CGI severity item scores and a final score of 2.2 (versus 2.6) on the CGI global improvement item. All doses of venlafaxine XR were well tolerated. CONCLUSIONS: Venlafaxine XR is an effective and well-tolerated option for the short-term treatment of generalized Anxiety disorder in outpatients without major depressive disorder.
